tradingkey.logo
tradingkey.logo

Illumina Inc

ILMN
124.460USD
-1.520-1.21%
Close 03/26, 16:00ETQuotes delayed by 15 min
15.36BMarket Cap
22.70P/E TTM

Illumina Inc

124.460
-1.520-1.21%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Illumina Inc

Currency: USD Updated: 2026-03-25

Key Insights

Illumina Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 32 out of 209 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 136.29.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Illumina Inc's Score

Industry at a Glance

Industry Ranking
32 / 209
Overall Ranking
113 / 4547
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Illumina Inc Highlights

StrengthsRisks
Illumina, Inc. is engaged in providing sequencing-and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 23.01, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 161.12M shares, decreasing 11.47% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 4.98K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.31.

Analyst Rating

Based on 22 analysts
Buy
Current Rating
136.292
Target Price
+10.10%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-25

The current financial score of Illumina Inc is 7.04, ranking 93 out of 209 in the Healthcare Equipment & Supplies industry. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 1.16B, representing a year-over-year increase of 4.98%, while its net profit experienced a year-over-year increase of 78.61%.

Score

Industry at a Glance

Previous score
7.04
Change
0

Financials

7.90

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.

Quality of Earnings

6.85

Operational Efficiency

7.36

Growth Potential

7.03

Shareholder Returns

6.05

Illumina Inc's Company Valuation

Currency: USD Updated: 2026-03-25

The current valuation score of Illumina Inc is 8.76, ranking 9 out of 209 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is 23.01, which is 49.20% below the recent high of 34.33 and 184.60% above the recent low of -19.47.

Score

Industry at a Glance

Previous score
8.76
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 32/209
Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-25

The current earnings forecast score of Illumina Inc is 7.09, ranking 149 out of 209 in the Healthcare Equipment & Supplies industry. The average price target is 120.00, with a high of 195.00 and a low of 80.00.

Score

Industry at a Glance

Previous score
7.09
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 22 analysts
Buy
Current Rating
136.292
Target Price
+8.19%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

92
Total
4
Median
7
Average
Company name
Ratings
Analysts
Illumina Inc
ILMN
22
Boston Scientific Corp
BSX
37
Intuitive Surgical Inc
ISRG
36
Edwards Lifesciences Corp
EW
35
Veeva Systems Inc
VEEV
33
Thermo Fisher Scientific Inc
TMO
29
1
2
3
...
19

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-25

The current price momentum score of Illumina Inc is 7.22, ranking 44 out of 209 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 135.54 and the support level at 116.09, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
7.28
Change
-0.06

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(1)
Neutral(4)
Buy(1)
Indicators
Value
Direction
MACD(12,26,9)
1.663
Neutral
RSI(14)
51.981
Neutral
STOCH(KDJ)(9,3,3)
77.557
Neutral
ATR(14)
4.870
High Vlolatility
CCI(14)
90.360
Neutral
Williams %R
18.913
Overbought
TRIX(12,20)
-0.140
Sell
StochRSI(14)
90.845
Buy
Moving Average
Sell(4)
Neutral(0)
Buy(2)
Indicators
Value
Direction
MA5
125.378
Sell
MA10
122.446
Buy
MA20
124.936
Sell
MA50
130.357
Sell
MA100
129.877
Sell
MA200
113.698
Buy

Institutional Confidence

Currency: USD Updated: 2026-03-25

The current institutional shareholding score of Illumina Inc is 10.00, ranking 1 out of 209 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 105.45%, representing a quarter-over-quarter increase of 1.61%. The largest institutional shareholder is The Vanguard, holding a total of 14.28M shares, representing 9.34% of shares outstanding, with 9.27% decrease in holdings.

Score

Industry at a Glance

Previous score
10.00
Change
0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name
Shares Held
Chg %
Capital World Investors
19.98M
+20.01%
The Vanguard Group, Inc.
Star Investors
14.55M
-3.50%
BlackRock Institutional Trust Company, N.A.
13.14M
-3.47%
State Street Investment Management (US)
6.00M
+6.81%
AQR Capital Management, LLC
3.40M
+3.10%
Loomis, Sayles & Company, L.P.
4.29M
+1.46%
WCM Investment Management
4.18M
-5.53%
Corvex Management LP
3.83M
--
Sessa Capital
4.69M
-0.76%
Geode Capital Management, L.L.C.
2.74M
-4.54%
1
2

Risk Assessment

Currency: USD Updated: 2026-03-25

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Illumina Inc is 6.49, ranking 59 out of 209 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.50. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

Score

Industry at a Glance

Previous score
6.49
Change
0
Beta vs S&P 500 index
1.49
VaR
+4.24%
240-Day Maximum Drawdown
+25.66%
240-Day Volatility
+43.50%

Return

Best Daily Return
60 days
+5.54%
120 days
+24.78%
5 years
+24.78%
Worst Daily Return
60 days
-10.40%
120 days
-10.40%
5 years
-14.63%
Sharpe Ratio
60 days
-0.45
120 days
+1.35
5 years
-0.35

Risk Assessment

Maximum Drawdown
240 days
+25.66%
3 years
+65.98%
5 years
+86.22%
Return-to-Drawdown Ratio
240 days
+2.55
3 years
-0.19
5 years
-0.17
Skewness
240 days
+2.07
3 years
+1.02
5 years
+0.86

Volatility

Realised Volatility
240 days
+43.50%
5 years
+44.87%
Standardised True Range
240 days
+3.20%
5 years
+5.58%
Downside Risk-Adjusted Return
120 days
+289.32%
240 days
+289.32%
Maximum Daily Upside Volatility
60 days
+29.80%
Maximum Daily Downside Volatility
60 days
+30.85%

Liquidity

Average Turnover Rate
60 days
+1.31%
120 days
+1.36%
5 years
--
Turnover Deviation
20 days
-30.51%
60 days
-5.18%
120 days
-1.32%

Peer Comparison

Healthcare Equipment & Supplies
Illumina Inc
Illumina Inc
ILMN
7.59 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Anika Therapeutics Inc
Anika Therapeutics Inc
ANIK
8.62 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc
TMO
8.47 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Bioventus Inc
Bioventus Inc
BVS
8.32 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
WST
8.23 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Edwards Lifesciences Corp
Edwards Lifesciences Corp
EW
8.10 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI